MedPath

FameWave Ltd.

🇮🇱Israel
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:1
Completed:1

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Phase 1
Completed
Conditions
Ovarian Cancer
Solid Tumor
Melanoma
Non Small Cell Lung Cancer
Pancreatic Cancer
Papillary Thyroid Cancer
Colorectal Adenocarcinoma
Interventions
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Drug: Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Drug: CM-24 and Nivolumab - Dose Escalation
First Posted Date
2021-02-01
Last Posted Date
2024-12-27
Lead Sponsor
Famewave Ltd.
Target Recruit Count
79
Registration Number
NCT04731467
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

Yale University, New Haven, Connecticut, United States

and more 15 locations

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Phase 1
Terminated
Conditions
Bladder Cancer
Ovarian Cancer
Non-small Cell Lung Carcinoma (NSCLC)
Melanoma
Colorectal Cancer
Gastric Cancer
First Posted Date
2015-01-27
Last Posted Date
2020-08-27
Lead Sponsor
Famewave Ltd.
Target Recruit Count
27
Registration Number
NCT02346955
Locations
🇺🇸

Call for Information (Investigational Site 0003), Los Angeles, California, United States

🇺🇸

Call for Information (Investigational Site 0004), New Haven, Connecticut, United States

🇮🇱

Merck Sharp & Dohme Co. Ltd., Hod Hasharon, Israel

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.